CD4 and cancer: The relevance of tumor MHC class II–restricted epitopes and their indirect presentation by DC and TAMs to trigger an antitumoral CD4 response, is additionally supported by previous findings describing the evolutionary pressure against MHC class II binding cancer mutations found in both mouse models (38), as well as in patients with cancer (40).